Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Chronic Lymphocytic Leukemia 2021 : Episode 11

Looking Toward the New Trends in CLL

December 30, 2021
By Susan M. O’Brien, MD
News
Video

Susan M. O’Brien, MD, on upcoming 2022 trends in chronic lymphocytic leukemia treatment.

EP: 1.Major Breakthroughs in Treating Chronic Lymphocytic Leukemia

EP: 2.Intriguing CLL Data From 2021 Conferences

EP: 3.Noncovalent BTK Inhibitors for Chronic Lymphocytic Leukemia

EP: 4.Approved BTK Inhibitors for Chronic Lymphocytic Leukemia

EP: 5.BTK Inhibitors in the Presence of 17p Deletions or TP53 Mutation in CLL

EP: 6.Combination Therapies for Chronic Lymphocytic Leukemia

EP: 7.Adverse Effects of Concern When Treating Chronic Lymphocytic Leukemia

EP: 8.Novel Mechanisms of Action in Chronic Lymphocytic Leukemia

EP: 9.Ongoing Trials of Combination Therapy for Treating CLL

EP: 10.Importance of Clinical Trial Enrollment for CLL

Now Viewing

EP: 11.Looking Toward the New Trends in CLL

EP: 12.Potential Approvals of CLL Combination Therapies in 2022

Susan M. O’Brien, MD: What I’d like to see in 2022 is that at least 1 of the noncovalent inhibitors, if not both, get FDA approved. That would be very exciting. Right now, patients do need to go on a clinical trial, which is well worth their doing, but it would be nice [for those agents to be approve] because it wouldn’t be limited to clinical trials. Those 2 drugs are going to really give us a fabulous option that we don’t have now [for patients who] develop resistance to the first-generation BTK inhibitors. They appear to be amazingly nontoxic and that’s partly because, if you look at the KINOME assays, they’re very specific for BTK, particularly pirtobrutinib [LOXO-305]. Not only is it nice to have great efficacy, but it’s also nice to have very low toxicity. Those will change practice, and I’m hoping that we are going to see FDA approval of those drugs or at least 1 of them in 2022.

Recent Videos
Current findings from the phase 1/2 CaDAnCe-101 trial show no predictive factors of improved responses with BGB-16673 in patients with CLL or SLL.
Both clinicians and patients should have as much information as possible to participate in shared decision-making for CLL care, says Jacob D. Soumerai, MD.
Sequencing different treatments in the first 3 lines of therapy represents a challenge in chronic lymphocytic leukemia, according to Deborah Stephens, DO.
Compared with second-generation tyrosine kinase inhibitors, asciminib was better tolerated in patients with chronic myeloid leukemia.
Bulkiness of disease did not appear to impact PFS outcomes with ibrutinib plus venetoclax in the phase 2 CAPTIVATE study.
A panel of 3 experts on CML
A panel of 3 experts on CML
A panel of 3 experts on CML
A panel of 3 experts on CML
Related Content
Advertisement

FDA Accepts sNDA for Decitabine/Cedazuridine Combo in Newly Diagnosed AML

FDA Accepts sNDA for Decitabine/Cedazuridine Combo in Newly Diagnosed AML

Ariana Pelosci
July 10th 2025
Article

A PDUFA date for decitabine/cedazuridine and venetoclax in newly diagnosed AML has been set for February 25, 2026.


Managing Cytokine Release Syndrome in Patients on CAR T-Cell Therapy

Managing Cytokine Release Syndrome in Patients on CAR T-Cell Therapy

Elizabeth Shpall, MD
May 29th 2019
Podcast

Ahead of the ASCO Annual Meeting, we discuss the assessment and management of cytokine release syndrome in patients with cancer with Elizabeth Shpall, MD.


The FDA has set a Prescription Drug User Fee Act date of October 25, 2025, for approving revumenib in this acute myeloid leukemia population.

FDA Grants Priority Review to Revumenib in R/R NPM1-Mutant AML

Russ Conroy
June 25th 2025
Article

The FDA has set a Prescription Drug User Fee Act date of October 25, 2025, for approving revumenib in this acute myeloid leukemia population.


Immunotherapy Approaches in AML

Immunotherapy Approaches in AML

Naval Daver, MD
January 17th 2019
Podcast

Cancer Network sat down with Dr. Naval Daver to discuss advancements and discoveries in immunotherapy for AML patients.


Olutasidenib Maintenance Shows Clinically Meaningful Activity in IDH1-Mutated AML

Olutasidenib Maintenance Shows Clinically Meaningful Activity in IDH1-Mutated AML

Jax DiEugenio
June 17th 2025
Article

Single-agent olutasidenib maintenance demonstrated clinically meaningful activity in patients with IDH1-mutated acute myeloid leukemia.


Ponatinib Shows Clinical Benefit Over Imatinib in MRD-Positive Ph+ ALL Post Induction

Ponatinib Shows Clinical Benefit Over Imatinib in MRD-Positive Ph+ ALL Post Induction

Chris Ryan
June 17th 2025
Article

Ponatinib extended EFS and PFS in patients with newly diagnosed, Ph-positive acute lymphoblastic leukemia who did not achieve MRD negativity after induction.

Related Content
Advertisement

FDA Accepts sNDA for Decitabine/Cedazuridine Combo in Newly Diagnosed AML

FDA Accepts sNDA for Decitabine/Cedazuridine Combo in Newly Diagnosed AML

Ariana Pelosci
July 10th 2025
Article

A PDUFA date for decitabine/cedazuridine and venetoclax in newly diagnosed AML has been set for February 25, 2026.


Managing Cytokine Release Syndrome in Patients on CAR T-Cell Therapy

Managing Cytokine Release Syndrome in Patients on CAR T-Cell Therapy

Elizabeth Shpall, MD
May 29th 2019
Podcast

Ahead of the ASCO Annual Meeting, we discuss the assessment and management of cytokine release syndrome in patients with cancer with Elizabeth Shpall, MD.


The FDA has set a Prescription Drug User Fee Act date of October 25, 2025, for approving revumenib in this acute myeloid leukemia population.

FDA Grants Priority Review to Revumenib in R/R NPM1-Mutant AML

Russ Conroy
June 25th 2025
Article

The FDA has set a Prescription Drug User Fee Act date of October 25, 2025, for approving revumenib in this acute myeloid leukemia population.


Immunotherapy Approaches in AML

Immunotherapy Approaches in AML

Naval Daver, MD
January 17th 2019
Podcast

Cancer Network sat down with Dr. Naval Daver to discuss advancements and discoveries in immunotherapy for AML patients.


Olutasidenib Maintenance Shows Clinically Meaningful Activity in IDH1-Mutated AML

Olutasidenib Maintenance Shows Clinically Meaningful Activity in IDH1-Mutated AML

Jax DiEugenio
June 17th 2025
Article

Single-agent olutasidenib maintenance demonstrated clinically meaningful activity in patients with IDH1-mutated acute myeloid leukemia.


Ponatinib Shows Clinical Benefit Over Imatinib in MRD-Positive Ph+ ALL Post Induction

Ponatinib Shows Clinical Benefit Over Imatinib in MRD-Positive Ph+ ALL Post Induction

Chris Ryan
June 17th 2025
Article

Ponatinib extended EFS and PFS in patients with newly diagnosed, Ph-positive acute lymphoblastic leukemia who did not achieve MRD negativity after induction.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.